Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS
Document Type and Number:
WIPO Patent Application WO/2020/203609
Kind Code:
A1
Abstract:
Provided is a medicinal drug for treating or preventing pruritus. As a medicinal drug for treating or preventing pruritus, the present invention uses, as an active ingredient, a compound that has an effect of blocking the Cav3.2 T-type calcium channel and that is represented by any one of general formulae (I)-(VI), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, or a solvate thereof.

More Like This:
JP4688682IL-17 homologous polypeptides and their therapeutic uses
JP2023100870METHOD FOR IMPROVING MITOPHAGY IN SUBJECT
JP2003534022INDUSTRIAL APPLICABILITY: Anti-RANK ligand monoclonal antibody useful for the treatment of RANK ligand-mediated disorder
Inventors:
GERALD W ZAMPONI (CA)
VINICIUS DE MARIA GADOTTI (CA)
KAWABATA ATSUFUMI (JP)
OGAWA TORU (JP)
TANAKA HIROTO (JP)
OOI ISAO (JP)
SAITO DAISUKE (JP)
HAYASHIDA KOHEI (JP)
YAMAMOTO KOHEI (JP)
Application Number:
PCT/JP2020/013542
Publication Date:
October 08, 2020
Filing Date:
March 26, 2020
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
NIPPON CHEMIPHAR CO (JP)
UTI LP (CA)
UNIV KINKI (JP)
International Classes:
A61P19/02; A61K31/397; A61K31/402; A61K31/4025; A61K31/4184; A61K31/422; A61K31/427; A61K31/4355; A61K31/437; A61K31/4439; A61K31/444; A61K31/454; A61K31/4545; A61K31/4709; A61K31/496; A61K31/497; A61K31/501; A61K31/506; A61K31/517; A61K31/5377; A61K31/5386; A61K31/541; A61K31/695; A61P17/04; A61P29/00; A61P43/00; C07D205/04; C07D207/14; C07D401/04; C07D401/12; C07D401/14; C07D403/04; C07D403/12; C07D403/14; C07D409/04; C07D413/04; C07D413/14; C07D417/04; C07D417/14; C07D471/04; C07D491/08; C07D491/107; C07D491/113; C07D498/08; C07F7/12
Domestic Patent References:
WO2011058932A12011-05-19
WO2017223474A12017-12-28
WO2009131196A12009-10-29
WO2015057655A12015-04-23
WO2005095327A12005-10-13
WO2020017569A12020-01-23
WO2020025517A12020-02-06
WO2019133635A12019-07-04
WO2019133632A12019-07-04
WO2014159969A12014-10-02
WO2012154274A12012-11-15
WO2017190609A12017-11-09
WO2016027195A12016-02-25
WO2013088404A12013-06-20
WO2010064707A12010-06-10
WO2017122754A12017-07-20
WO2013026914A12013-02-28
WO2015073528A12015-05-21
WO2013144295A12013-10-03
WO2014010748A12014-01-16
WO2008125337A22008-10-23
WO2016100154A12016-06-23
WO2012125893A12012-09-20
WO2008013130A12008-01-31
Foreign References:
JP2014505037A2014-02-27
JP2018537501A2018-12-20
CN105837577A2016-08-10
JP2008543762A2008-12-04
CN107556318A2018-01-09
JP2016525562A2016-08-25
JP2008509910A2008-04-03
JP2002088073A2002-03-27
JPS5515495A1980-02-02
Other References:
LEPRI, S. ET AL.: "Structure-metabolism relationships in human-AOX: Chemical insights from a large database of aza-aromatic and amide compounds", PNAS, vol. 114, no. 16, 3 April 2017 (2017-04-03), pages E3178 - E3187, XP055689694, DOI: 10.1073/pnas.1618881114
SUN YG ET AL.: "A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord.", NATURE, vol. 448, no. 7154, 2007, pages 700 - 703
SUN YG ET AL.: "Cellular basis of itch sensation.", SCIENCE, vol. 325, no. 5947, 2009, pages 1531 - 1534
WANG XL ET AL.: "Hydrogen sulfide-induced itch requires activation of Cav3.2 T-type calcium channels in mice.", SCIENTIFIC REPORTS, vol. 5, 2015, pages 16768
CHRISTIAN A.G.N. MONTALBETTI ET AL., TETRAHEDRON, vol. 61, no. 46, 2005, pages 10827 - 10852
COTTET FABRICE ET AL., EUR. J. ORG. CHEM., no. 2, 2002, pages 327 - 330
RADOSLAW LAUFER, BIOORG. MED. CHEM, vol. 22, no. 17, 2014, pages 4968 - 4997
KYOJI TOMITA, J. MED. CHEM, vol. 45, no. 25, 2002, pages 5564 - 5575
Attorney, Agent or Firm:
CHIGUSA Shinichi et al. (JP)
Download PDF:
View/Download PDF      PDF Help



 
Previous Patent: METHOD FOR DETERMINING ROASTING CONDITIONS OF COPPER CONCENTRATES AND METHOD FOR ROASTING COPPER CON...

Next Patent: USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING RHEUMATOID ARTHRITIS